Argenx Calls Extraordinary Meeting to Discuss Remuneration Policy
Argenx SE, a global leader in immunology, has called for an Extraordinary General Meeting of shareholders on Tuesday, November 18, 2025, at 14:00 CET. The meeting will take place at the offices of Freshfields LLP in Amsterdam, the Netherlands. Shareholders are encouraged to attend in person, by proxy, or use an e-voting system. The formal notice of convocation, agenda, and other documents are available on the argenx website and can be obtained via email upon request.
Argenx aims to discuss and potentially adopt a revised remuneration policy during the election. The company, known for developing and commercializing the first approved neonatal Fc receptor (FcRn) blocker, is committed to translating immunology breakthroughs into a portfolio of novel antibody-based medicines through its Immunology Innovation Program. Shareholders are urged to use the voting by (electronic) proxy option to ensure their voices are heard.
Argenx is currently evaluating the broad potential of its FcRn blocker in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines. The company's goal is to improve the lives of people suffering from severe autoimmune diseases.
The Extraordinary General Meeting of shareholders is an opportunity for argenx to update its remuneration policy and engage with its shareholders. The meeting is open to all shareholders, who are encouraged to participate in person, by proxy, or through e-voting. The formal notice of convocation and other documents are readily available on the argenx website and via email upon request.
Read also:
- Thieves Steal Unique Sculptures from Redwood National Park's Grove of Titans
- Strategizing the Integration of Digital Menus as a Core Element in Business Operations
- Financial Actions of BlockDAG Following Inter and Borussia Agreements: Anticipating Future Steps
- International powers, including France, Germany, and the UK, advocate for the reinstatement of sanctions against Iran.
